RedHill Biopharma Ltd (RedHill) is a specialty biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines for gastrointestinal (GI) diseases and cancer.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

RedHill research and development (R&D) is focused at developing its therapeutic candidates. The company is evaluating RHB-104 in Phase III clinical trials for Crohn's disease; RHB-204 in Phase III clinical trials for NTM infections; RHB-102 (Bekinda) in Phase III clinical trials for gastroenteritis and gastritis. It is also investigating Opaganib, which is in Phase III clinical trials for the treatment of patients with severe COVID-19 pneumonia; RHB-107 upamostat in Phase III clinical trials for cancer, gastrointestinal diseases, and COVID-19. In FY2022, the company invested US$7.3 million on R&D. As of December 31, 2022, the company owns 415 issued patents and 90 patent applications.